About this Research Topic
This Research Topic is intended to provide: 1) a comprehensive overview of the main molecular mechanisms that are currently known to be involved in prostate tumorigenesis and progression; 2) information on the most recent results from applications of genomic, epigenomic and metabolomic technologies; and 2) up-to-date information on new therapeutic agents proposed and tested in preclinical/clinical settings.
The following areas of investigation will be included:
1) Role of steroid hormone signaling dysregulations in the pathogenesis of androgen-dependent and castration-resistant prostate cancer and therapeutic implications; Identification of mutations, polymorphisms and epigenetic modifications that may affect androgen receptor binding to DNA and response to hormonal agents; Androgen receptor co-regulators.
2) Analyses of copy number alterations, gene fusions, newly emerging genomic rearrangements and genome-wide association studies (GWAS).
3) Studies including results from genome-wide approaches and metabolomics. Identification of new molecular markers of disease.
4) Results on the utilization of radiolabeled molecules for prostate cancer imaging in patients with disease at different clinical stage.
5) Generation of engineered mouse models and mouse xenografts to be utilized in the investigation of molecular phenotypes of prostate cancer as well as in preclinical studies.
6) Identification and therapeutic testing of small molecules and compounds; review of clinical trials conducted with new pharmacological agents.
The Research Topic would include:
Androgen and estrogen receptors; resistance to hormonal agents; genomics and epigenomics; metabolomics; diagnostic and prognostic biomarkers in tissues and biological fluids; mouse models; new therapeutic agents and targeted therapies.
The following areas of investigation will be included:
1) Role of steroid hormone signaling dysregulations in the pathogenesis of androgen-dependent and castration-resistant prostate cancer and therapeutic implications; Identification of mutations, polymorphisms and epigenetic modifications that may affect androgen receptor binding to DNA and response to hormonal agents; Androgen receptor co-regulators.
2) Analyses of copy number alterations, gene fusions, newly emerging genomic rearrangements and genome-wide association studies (GWAS).
3) Studies including results from genome-wide approaches and metabolomics. Identification of new molecular markers of disease.
4) Results on the utilization of radiolabeled molecules for prostate cancer imaging in patients with disease at different clinical stage.
5) Generation of engineered mouse models and mouse xenografts to be utilized in the investigation of molecular phenotypes of prostate cancer as well as in preclinical studies.
6) Identification and therapeutic testing of small molecules and compounds; review of clinical trials conducted with new pharmacological agents.
The Research Topic would include:
Androgen and estrogen receptors; resistance to hormonal agents; genomics and epigenomics; metabolomics; diagnostic and prognostic biomarkers in tissues and biological fluids; mouse models; new therapeutic agents and targeted therapies.
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
